Chief Scientific Officer, Abzena
Prior to joining Abzena, Campbell spent 20 years working in the biotech sector for companies such as Cantab Pharmaceuticals, Piramed Pharma and immune Targeting Systems. He has led the development of many novel vaccine and therapeutic technologies targeting infectious disease, cancer, inflammatory and autoimmune disease, taking them through value inflexion points in support of investment and partnering outcomes.
Campbell has a PhD in Immunology from the University of Manchester and has published numerous papers on immune mechanisms and novel drug development. He is currently studying for an Executive MBA at the Judge Business School, University of Cambridge.
16 November 2020
BOOK YOUR PLACE NOW